Ensign Peak Advisors Inc Decreases Holdings in Janux Therapeutics, Inc. $JANX

Ensign Peak Advisors Inc reduced its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 96.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,300 shares of the company’s stock after selling 285,450 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Janux Therapeutics were worth $215,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Janux Therapeutics by 26.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,125 shares of the company’s stock worth $192,000 after purchasing an additional 1,488 shares in the last quarter. US Bancorp DE boosted its holdings in Janux Therapeutics by 2,402.9% in the first quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after acquiring an additional 1,658 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Janux Therapeutics by 6.7% during the first quarter. Vanguard Group Inc. now owns 2,278,660 shares of the company’s stock worth $61,524,000 after acquiring an additional 142,328 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Janux Therapeutics by 7.2% during the first quarter. Deutsche Bank AG now owns 99,691 shares of the company’s stock worth $2,692,000 after acquiring an additional 6,662 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of Janux Therapeutics during the first quarter valued at about $3,339,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 16,665 shares of the company’s stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $30.06, for a total value of $500,949.90. Following the sale, the insider owned 82,139 shares in the company, valued at $2,469,098.34. This represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 29.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on JANX. Wall Street Zen upgraded shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a report on Wednesday, October 8th. Piper Sandler began coverage on shares of Janux Therapeutics in a report on Monday, August 18th. They set an “overweight” rating and a $42.00 price objective on the stock. Truist Financial initiated coverage on Janux Therapeutics in a research note on Wednesday, September 10th. They issued a “buy” rating and a $100.00 target price for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $45.00 price target on shares of Janux Therapeutics in a research report on Wednesday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $79.17.

Janux Therapeutics Price Performance

JANX stock opened at $33.99 on Tuesday. The company has a market capitalization of $2.04 billion, a P/E ratio of -20.23 and a beta of 2.82. Janux Therapeutics, Inc. has a 12 month low of $21.73 and a 12 month high of $71.71. The firm’s fifty day simple moving average is $27.29 and its 200-day simple moving average is $25.43.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. As a group, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.